

**נספח 1:****הודעה על חזרה לשיווק של תכשיר****Erelzi® 50 solution for injection in pre-filled pens**

תאריך ההודעה: 27/11/2023

בעל הרישום: Novartis Israel Ltd. מודיע על חזרה לשיווק של:

163-21-36037-00	מספר רישום
ארלזי 50	שם התכשיר בעברית
ERELZI 50	שם התכשיר באנגלית
SOLUTION FOR INJECTION	צורת מינון
S.C	דרך מתן
ETANERCEPT	מרכיב פעיל
50 MG / 1 ML	חוזק
ראה התוויה בדף מצורף	התוויה
11/10/2023	תאריך תחילת הפסקת השיווק
31/10/2023	תאריך צפי לסיום הפסקת השיווק
27/11/2023	תאריך חזרה לשיווק (יש למלא משבצת זאת עם חזרת התכשיר לשיווק בפועל)
כן	הכללה בסל הבריאות: כן / לא
סיבות תפעוליות	סיבת הפסקת השיווק: סיבות תפעוליות / סיבות מסחריות
4 Pre-filled pens	גודל/י אריזה (נא לרשום את כל הגדלים הרלוונטיים להודעה זאת)
<ul style="list-style-type: none"><li>Erelzi 25</li><li>Erelzi 50 - 4 Pre-filled syringes</li></ul>	זמינות של גודל אריזה אחר או חוזק אחר של התכשיר

עמוד 1 מתוך 2

**Novartis Israel Ltd.**

P.O.Box 7126, Tel Aviv

Tel: 972-3-9201111 Fax: 972-3-9229244

**נוברטיס ישראל בע"מ.**

ת.ד. 7126, תל אביב

טלפון: 03-9201111 פקס: 03-9229244

**Rheumatoid arthritis**

Erelzi is indicated for the treatment of active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate. Erelzi can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Etanercept, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.

**Juvenile idiopathic arthritis**

Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.

Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.

Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.

**Psoriatic arthritis**

Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.

**Axial spondyloarthritis**

**Ankylosing spondylitis (AS)**

Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

**Non-radiographic axial spondyloarthritis**

Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs).

**Plaque psoriasis**

Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

**Paediatric plaque psoriasis**

Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.